Skip to main content
Clinical Trials/ISRCTN37143632
ISRCTN37143632
Completed
未知

Impact on physical fitness and cognitive ability in school children from southern Côte d'Ivoire after treatment against soil-transmitted helminths and schistosomiasis

Swiss Tropical and Public Health Institute (Switzerland)0 sites300 target enrollmentNovember 19, 2012

Overview

Phase
未知
Intervention
Not specified
Conditions
eglected tropical diseases (soil-transmitted helminth and schistosomiasis infections) and malaria
Sponsor
Swiss Tropical and Public Health Institute (Switzerland)
Enrollment
300
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 19, 2012
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Swiss Tropical and Public Health Institute (Switzerland)

Eligibility Criteria

Inclusion Criteria

  • 1\. Primary school child, aged 8\-15 years, male or female
  • 2\. Written informed consent by a parent/guardian on behalf of the child
  • 3\. Submission of 1 urine, 1 stool and 1 finger\-prick blood sample at baseline
  • 4\. Completion of clinical, anthropometric and haemoglobin measurements at baseline
  • 5\. Completion of 20 m shuttle run test at baseline
  • 6\. Completion of grip strength test and standing broad jump test at baseline
  • 7\. Completion of cognitive testing
  • 8\. Absence of difficult health condition (clinical malaria, severe anemia, respiratory disease or other major illnesses) as assessed by a medical doctor at baseline
  • 9\. No known or reported drug allergy to albendazole or praziquantel
  • 10\. Treatment with albendazole and praziquantel

Exclusion Criteria

  • 1\. Children below the age of 8 years or above 15 years
  • 2\. No written informed consent
  • 3\. No complete set of urine, stool and blood sample submitted at baseline
  • 4\. Presence of medical condition that prevents child from completing the physical fitness and strength tests
  • 5\. Known or reported drug allergy to albendazole or praziquantel
  • 6\. Absence/refusal of albendazole and/or praziquantel treatment
  • 7\. Attending other clinical trials during the study period

Outcomes

Primary Outcomes

Not specified

Similar Trials